Literature DB >> 15131044

Loss of 14-3-3sigma in prostate cancer and its precursors.

Liang Cheng1, Chong-Xian Pan, Jian-Ting Zhang, Shaobo Zhang, Michael S Kinch, Lang Li, Lee Ann Baldridge, Christopher Wade, Zhiqiang Hu, Michael O Koch, Thomas M Ulbright, John N Eble.   

Abstract

PURPOSE: The 14-3-3 family proteins are highly conserved over many mammalian species. The sigma isoform (also called HME-1 or stratifin) is expressed in epithelial cells. Loss of 14-3-3sigma is associated with failure to arrest the cell cycle at the G(2)-M phase checkpoint after DNA damage that leads to increased G(2)-type chromosomal aberrations. The role of 14-3-3sigma in prostatic carcinogenesis is uncertain. EXPERIMENTAL
DESIGN: We studied one hundred and eleven specimens of invasive prostate adenocarcinoma with paired, adjacent high-grade prostatic intraepithelial neoplasia and normal prostate epithelium. Immunohistochemistry was used to detect the expression of 14-3-3sigma. The findings were correlated with various clinical pathological parameters.
RESULTS: 14-3-3sigma is ubiquitously expressed at high levels in normal prostate epithelium. Its expression is significantly decreased in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Ninety percent of samples of prostatic intraepithelial neoplasia had no or low 14-3-3sigma expression. Ninety-seven percent of invasive adenocarcinomas had no or low 14-3-3sigma expression. In most specimens (90%), suppression of 14-3-3sigma expression occurred during the development of prostatic intraepithelial neoplasia from normal epithelium.
CONCLUSIONS: Our data suggest that loss of 14-3-3sigma contributes to the development of prostate adenocarcinoma. 14-3-3sigma expression is significantly decreased during the progression of normal prostatic epithelium to prostatic intraepithelial neoplasia and invasive cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131044     DOI: 10.1158/1078-0432.ccr-03-0652

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  32 in total

1.  Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer.

Authors:  Xiaoyan Wang; Robert J Hickey; Linda H Malkas; Michael O Koch; Lang Li; Shaobo Zhang; George E Sandusky; David J Grignon; John N Eble; Liang Cheng
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

2.  CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.

Authors:  S M Pulukuri; J S Rao
Journal:  Oncogene       Date:  2006-06-19       Impact factor: 9.867

3.  Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.

Authors:  Brandon J Metge; Andra R Frost; Judy A King; Donna Lynn Dyess; Danny R Welch; Rajeev S Samant; Lalita A Shevde
Journal:  Clin Exp Metastasis       Date:  2008-06-20       Impact factor: 5.150

4.  14-3-3sigma, the double-edged sword of human cancers.

Authors:  Zhaomin Li; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  Am J Transl Res       Date:  2009-06-08       Impact factor: 4.060

5.  Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers.

Authors:  Zhaomin Li; Zizheng Dong; David Myer; Michele Yip-Schneider; Jianguo Liu; Ping Cui; C Max Schmidt; Jian-Ting Zhang
Journal:  BMC Cancer       Date:  2010-11-01       Impact factor: 4.430

6.  TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.

Authors:  Ken-Ichi Takayama; Takashi Suzuki; Tomoaki Tanaka; Tetsuya Fujimura; Satoru Takahashi; Tomohiko Urano; Kazuhiro Ikeda; Satoshi Inoue
Journal:  Oncogene       Date:  2018-01-30       Impact factor: 9.867

7.  14-3-3sigma Modulates pancreatic cancer cell survival and invasiveness.

Authors:  Divas Neupane; Murray Korc
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

8.  Elovl6 is a poor prognostic predictor in breast cancer.

Authors:  Yin-Hsun Feng; Wei-Yu Chen; Yu-Hsuan Kuo; Chao-Ling Tung; Chao-Jung Tsao; Ai-Li Shiau; Chao-Liang Wu
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

9.  14-3-3 proteins modulate the ETS transcription factor ETV1 in prostate cancer.

Authors:  Sangphil Oh; Sook Shin; Stan A Lightfoot; Ralf Janknecht
Journal:  Cancer Res       Date:  2013-06-17       Impact factor: 12.701

10.  Presence and distribution of 14-3-3 proteins in human ocular surface tissues.

Authors:  Jwalitha Shankardas; Michelle Senchyna; Slobodan D Dimitrijevich
Journal:  Mol Vis       Date:  2008-12-31       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.